In GL261, TIM-3 expression by T cells was reported to increase from day 14 post-implantation, supporting the approach of targeting both checkpoint inhibitors in GL261 as well as in other glioma models [9, 10, 52]. The gene discussed is HAVCR2; the disease is central nervous system cancer.